IDEXX Laboratories Stock News

IDEXX Laboratories, Inc. delivered strong Q1 FY25 results with 4.7% organic revenue and 7% adjusted EPS growth, despite weak US clinical visits. I see catalysts ahead: potential U.S. tax cuts, normalization of consumer spending, and robust pricing power supporting profit growth. Management guides for 6%-9% organic revenue and 8%-12% adjusted EPS growth in FY25; I model 8.2% revenue growth and m...

WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced that Andrew Emerson, Executive Vice President and Chief Financial Officer, and Tina Hunt, Executive Vice President, Global Strategy and Commercial, will participate in a fireside chat at the Stifel Jaws & Paws Conference on Wednesday, May 28, 2025 from 10:55 ...

IDEXX Laboratories, Inc. (NASDAQ:IDXX ) Q1 2025 Earnings Conference Call May 1, 2025 8:30 AM ET Company Participants Andrew Emerson - EVP, CFO and Treasurer Jay Mazelsky - President and CEO Conference Call Participants Michael Ryskin - Bank of America Erin Wright - Morgan Stanley Jon Block - Stifel Brandon Vazquez - William Blair Dan Clark - Leerink Partners David Westenberg - Piper Sandler Nav...

Animal diagnostics maker IDEXX Laboratories on Thursday raised its annual profit forecast after it beat Wall Street estimates for quarterly profit, as it benefited from customer retention and increased demand for its tests and equipment.

WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced first quarter results. “IDEXX drove solid execution in the first quarter while advancing key enablers of our innovation-driven growth strategy. At the end of March, IDEXX launched a first-of-its-kind innovation, IDEXX Cancer Dx™, in our North American referen...

WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2025 first quarter financial results for Thursday, May 1, 2025, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day. Individuals can access a live webcast of the conference call, ...

Healthcare diagnostics equipment manufacturer, Idexx Laboratories (IDXX -1.54%), is the global leader in pet care.

Upgraded IDEXX to 'Buy' with a $450 price target due to oncology business expansion and share repurchase program. IDEXX's oncology market entry with Cancer Dx panel in March 2025 could drive significant growth and new revenue streams. IDEXX's share repurchase program is robust, with $837 million repurchased in FY24 and a plan for $1.5 billion in FY25.